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Summary
Adverse hypertrophic scars can form after healing of full-thickness skin wounds. Currently, reliable animal 
and in vitro models to identify and test novel scar reducing therapeutics are scarce. Here we describe  
the development and validation of a tissue-engineered human hypertrophic scar (HTscar) model based on 
reconstructed epidermis on a dermal matrix containing adipose derived mesenchymal stem cells (ASC). 
Although obtained from normal, healthy skin, ASC, in contrast to dermal mesenchymal cells, were found 
to facilitate HTscar formation. Quantifiable HTscar parameters were identified: contraction; thickness 
of dermis, collagen-1 secretion, epidermal outgrowth, epidermal thickness, and cytokine secretion (IL-6, 
CXCL8). The model was validated with therapeutics currently used for treating scars (5-fluorouracil, 
triamcinolon) and a therapeutic known to be unsuccessful in scar reduction (1,25-dihydroxyvitamin-D3). 
Furthermore, it was shown that atorvastatin, but not retinoic-acid, may provide a suitable alternative for 
scar treatment. Each therapeutic selectively affected a different combination of parameters, suggesting 
combined therapy may be most beneficial. This animal-free hypertrophic scar model may provide an 
alternative model for mechanistic studies as well as a novel in vitro means to test anti-scar therapeutics, 
thereby reducing the use of animals.
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1  Introduction
Cuteanous wound healing is a natural, complex response to tis-
sue injury and normally results in a scar. the most desirable scar 
is thin and flat and is mostly seen after superficial injury. This 
type is called a normotrophic scar (Ntscar). extensive trauma, 
deep burns, and sometimes even standard surgery, however, can 
result in wound closure with an adverse scar formation which is 
red, firm, raised, itchy, and painful. This adverse scar is known 
as a hypertrophic scar (Htscar) (Bayat et al., 2003). the quality 
of life of patients with HTscars can be severely affected due to 
loss of joint mobility, contractures, and disfigurements which 
lead to accompanying psychological problems (like depression 
and social avoidance) (Bayat et al., 2003). 
HTscars occur more often after full-thickness wounding, 
where no viable dermis is left and adipose tissue is exposed. 
Therefore, the deeper the wound, the greater the possibility 
of HTscar formation (Deitch et al., 1983). The pathogenesis 
of HTscar formation in humans is not well understood, and 
although there are various treatment strategies, it is gener-
ally accepted that current strategies are still far from optimal 
(Atiyeh, 2007; Niessen et al., 1999). A major limitation in the 
progress of scar management is the lack of physiologically 
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relevant human models to explore the pathogenesis of HT-
scar formation and to test new therapeutics. Today, patients, 
animal models, and in vitro cell culture models are used to 
study skin scar formation. Patient studies are essential, but 
are limited by logistical and ethical problems. Common al-
ternatives are animal studies. Despite the large number of 
studies describing pigs, mice, rabbits, and other animals as 
models to investigate hypertrophic scarring, the wound heal-
ing process in these species presents significant differences 
when compared with human scarring (Ramos et al., 2008). 
Pig skin most closely represents human skin and the red du-
rac pig model has recently been validated, since these pigs 
develop HTscars similar to human HTscars in a number of 
ways (Zhu et al., 2007). However, extensive research with 
this model is limited due to the lack of pig specific biomark-
ers (such as those detected by monoclonal antibodies). Rab-
bit skin also shows some similarities to human scar forma-
tion, but the rabbit ear scar model (Morris et al., 1997) has 
similar restrictions to the pig model. Mouse models are used 
most extensively, even though mouse skin physiology poorly 
represents human skin and mice do not form adverse scars 
after wounding. Therefore, in order to humanize mouse mod-
els, studies have been described using CxCR3–/– mice (Yates 
et al., 2010) and transplanting human skin onto the backs of 
nude mice (Yang et al., 2007; Ramos et al., 2008). In addi-
tion to difficulties in interpreting results due to differences in 
skin physiology (and, in particular, scar formation), inflict-
ing large, full-thickness trauma and burn wounds to animals 
has substantial ethical implications world-wide. In vitro cell 
culture models have been used to gain insight into different 
aspects of scar pathogenesis. Adipose derived mesenchymal 
cells, for example, have been described as having a number 
of similar characteristics to mesenchymal cells found within 
HTscar tissue, e.g., both are α-SMA positive (El-Ghalbzouri 
et al., 2004; van den Bogaerdt et al., 2009; van der Veen et 
al., 2011; Wang et al., 2008). Additionally, a scratch assay has 
been described in which an increase in the single parameter 
Connective tissue Growth Factor (CtGF) has been proposed 
for testing scar therapeutics (Moon et al., 2012). However, no 
attempts have been made so far to create a robust and physi-
ologically relevant in vitro HTscar model for in vitro testing 
of therapeutics with multiple scar-forming parameters. With 
increasing pressure from the EU (Directive 2010/63/EU) for 
the replacement, reduction, and refinement of the use of ani-
mals models, there is an urgent need to develop a physiologi-
cally relevant in vitro human Htscar model to investigate the 
pathogenesis of HTscar formation. This, in turn, can facilitate 
identification and testing of new therapeutics leading to novel 
treatment strategies.
We have developed and validated a tissue engineered Ht-
scar model consisting of a reconstructed epidermis on a der-
mal matrix populated with mesenchymal cells. We compared 
full-thickness skin equivalents (SE) constructed from mesen-
chymal stem cells isolated from the deep cutaneous adipose 
tissue (ASC) with SE constructed from more superficial mes-
enchymal stromal cells found within the reticular dermis (R-
DSC) and papillary dermis (P-DSC) in order to mimic Htscar 
formation, NTscar formation, and Nskin, respectively. We hy-
pothesized that ASC in the exposed wound bed might most 
rapidly regenerate dermal tissue in order to close life threat-
ening, deep cutaneous wounds at the cost of HTscar forma-
tion, whereas more superficial wounds are repaired from DSC 
within the flanking and underlying dermis, generally resulting 
in NTscar formation. 
In order to develop, validate, and further test the HTscar 
model, a number of quantifiable parameters typical for HT-
scars were identified: 1) contraction, since HTscars are highly 
contractile (Ehrlich et al., 1994); 2) thickness of the dermis; 3) 
collagen-1 secretion, since more connective tissue is formed 
in Htscars than in Ntscars (van der Veer et al., 2009a); 4) the 
degree of epithelialization, since it has been described that the 
extent of HTscar formation corresponds with delayed wound 
closure (Deitch et al., 1983); and 5) thickness of the regen-
erating epidermis, since it is known that HTscars have more 
epidermal cell layers than Ntscars (Andriessen et al., 1998). 
In addition to the scar forming parameters, we assessed the 
secretion of two cytokines known to contribute to wound heal-
ing, IL-6 and CXCL8 (Broughton et al., 2006). The HTscar 
model was validated with therapeutics generally used in the 
clinic for scar treatment (5-fluorouracil and a triamcinolone 
(Kenacort®-A40)) (Mustoe et al., 2002; Wang et al., 2009) 
and a therapeutic known to be unsuccessful in scar reduction 
(1,25-dihydroxy vitamin D3) (van der Veer et al., 2009b). the 
HTscar model was further tested with two potential scar-reduc-
tion therapeutics (all-trans-retinoic acid and atorvastatin cal-
cium salt trihydrate) (Aarons et al., 2007; Wang et al., 2009).
2  Materials and methods
Normal skin and scar tissue
Human adult skin samples were obtained from healthy in-
dividuals undergoing abdominal dermolipectomy or breast 
reduction surgery (n=9; age: 25-50 years; sex: 8 x female, 
1 x male). Scar tissue samples were obtained from patients 
who underwent plastic surgery for scar excision (HTscar n=8; 
age: 25-55 years; sex: 7 x female, 1 x male; location: abdo-
men, breast, and flank; age of scar: >1 year and NTscar n=7; 
age: 15-60 years; sex: 6 x female, 1 x male; location: abdo-
men and breast; age of scar: >1 year). HTscars were defined as 
raised above skin level (>1 mm) for at least 1 year and NTscars 
were defined as never raised above skin level. VU University 
Medical Center approved all the experiments described in this 
manuscript. the study was conducted according to the Decla-
ration of Helsinki1.
Cell isolation and culture of normal healthy skin 
Epidermal keratinocytes (KC) were isolated from healthy 
(non-scarred) human adult skin and cultured as described ear-
lier (Waaijman et al., 2010). Keratinocytes were cultured until 
1 http://www.wma.net/en/30publications/10policies/b3/
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culture period of 5 weeks for histological analysis and culture 
supernatants were collected for ELISA. The cultures received 
new culture medium twice a week.
Application of therapeutics 
Se containing ASC were generated as described above. thera-
peutics were added to the culture medium from the first me-
dium renewal after starting the culture. The constructs were 
cultured with 10-7 M all-trans-retinoic acid (Sigma-Aldrich, 
St. louis, MO, USA), 10-8 M 5-Fluorouracil (Sigma-Aldrich, 
St. louis, MO, USA), 10-7 M Atorvastatin calcium salt trihy-
drate (Sigma-Aldrich, St. louis, MO, USA) (all dissolved in 
0.01% dimethylsulfoxide (DMSO), or 10-5 M Kenacort®-A40 
(Bristol-Myers Squibb B.V., Woerden, the Netherlands) (dis-
solved in 0.01% benzyl alcohol), or 10-8 M 1,25-dihydroxy vi-
tamin D3 (Sigma-Aldrich, St. louis, MO, USA) (dissolved in 
0.0095% ethanol). Corresponding vehicles were used as con-
trols. The concentrations were determined from dose response 
studies on ASC monolayers. Concentrations were chosen at 
which ASC metabolic activity, corresponding to proliferation 
(2 days’ exposure), was not inhibited in the Mtt assay (see 
below). 
Histological and immunohistochemical analysis
Paraffin embedded sections of normal tissue, scar tissue, and 
SE were used for morphological (haematoxylin and eosin 
staining) and immunohistochemical analysis (alpha-smooth 
muscle actin (α-SMA), clone 1A4; 1:200, Dako, Glostrup, 
Denmark) (Waaijman et al., 2010). The dermal thickness of SE 
was quantified from photos of H&E stainings (Nikon Eclipse 
80i Düsseldorf, Germany) taken at 200-fold magnification us-
ing NIS-Elements AR 2.10 software. The epidermal thickness 
was quantified by taking the mean of the number of living cell 
layers at 5 different regions within a single tissue section.
Measurement of matrix contraction and outgrowth of epidermis
Matrix contraction and outgrowth of the epidermis were de-
termined by taking photographs of the constructs at the first 
medium change and then again at the time of harvesting of the 
cultures. Photographs were taken with a Nikon Coolpix 5400 
digital camera (Japan). The surface area of the constructs and 
the outgrowth of the epidermis outside of the original 1 cm 
diameter seeding area were determined using NIS-elements 
AR 2.10 imaging software (Nikon). 
Keratinocyte migration 
Chemotactic migration of keratinocytes towards DE-condi-
tioned medium (dose response of 0.3%, 3%, and 30%) with 
the aid of a modified Boyden well chamber technique using a 
24-transwell system with 8 μm was assessed and quantified as 
previously described (Kroeze et al., 2011).
Cell proliferation
A MTT assay was used to measure mitochondrial activity of 
ASC, which is representative of the viable number of cells 
(Mosmann, 1983). The assay was performed as described by 
the supplier (Sigma-Aldrich, St. louis, MO, USA).
80% confluence and then stored in the vapor phase of liquid 
nitrogen for later use.
Papillary dermal, reticular dermal, and adipose-derived 
mesenchymal cells were isolated by collagenase type II/dis-
pase II treatment from healthy (non-scarred) human adult skin 
as previously described by Kroeze et al. (2009). In short, split 
thickness skin (0.4 mm) was removed using a dermatome 
(Acculan II, Braun, tuttligen, Germany) to separate the papil-
lary dermis from reticular dermis and adipose tissue (Schafer 
et al., 1985). the cells in the papillary dermis (upper layer) 
are further referred as P-DSC. From the remaining reticular 
dermis all adipose tissue was removed. Cells in the reticular 
dermis are further referred to as R-DSC. ASC were isolated in 
the same way as P-DSC and R-DSC. All mesenchymal cells 
were cultured under identical conditions and upon reaching 
80% confluence were stored in the vapor phase of liquid ni-
trogen until required. Notably, within a single experiment, 
KC, P-DSC, R-DSC, and ASC were all from the same donor. 
Cells at passage 3 were used to construct skin equivalents 
(SE), which consist of reconstructed epidermis on fibroblast 
populated dermal matrix, and dermal equivalents (De) which 
are the same but lack an epidermis. Of note, P-DSC, and R-
DSC are the same cell population often referred to as dermal 
fibroblasts (Kroeze et al., 2009). 
Skin equivalents (SE) and dermal equivalents (DE) 
In this study we choose the sponge-like collagen-elastin-
matrix (Matriderm®; Dr. Suwelack Skin & Health Care, 
Billerbeck, Germany) since it provides an initial scaffold for 
seeding the cells into but is then very easily remodeled by 
the cells within the matrix – thus enabling potential scar-like 
phenotypes to be formed. Mesenchymal cells (4 x 105) were 
seeded into the collagen-elastin-matrix (2.2 x 2.2 cm) and cul-
tured submerged for three weeks in culture medium contain-
ing DMEM (BioWhittaker, Verviers, Belgium)/Ham’s F-12 
(Invitrogen, GIBCO, Paisley, UK) (3:1), 2% UltroSerG (UG) 
(BioSepra SA, Cergy-Saint-Christophe, France), 1% penicil-
lin/streptomycin (P/S) (Invitrogen, GIBCO, Paisley, UK), 
5 μg/ml insulin, 50 μg/ml ascorbic acid, and 5 ng/ml epider-
mal growth factor (EGF). Unless otherwise stated, all culture 
additives were obtained from Sigma-Aldrich (St. Louis, MO, 
USA). Medium obtained after the last refreshment before ke-
ratinocytes were seeded onto the surface of DE was collected 
and is referred to as medium of DE. This conditioned DE me-
dium was used for keratinocyte migration assays as described 
below. After 3 weeks of culturing, KC (5 x 105 cells/culture) 
were seeded onto the surface of mesenchymal cell-populated 
matrixes. Then cultures were submerged for 4 days in DMEM/
Ham’s F-12 (3:1), 1% UG, 1% P/S, 1 µM hydrocortisone, 1 
µM isoproterenol, 0.1 µM insulin, and 1 ng/ml KGF. Here-
after, SE were cultured at the air-liquid interface in DMEM/
Ham’s F-12 (3:1), 0.2% UG, 1% P/S, 1 µM hydrocortisone, 1 
µM isoproterenol, 0.1 µM insulin, 10 μM l-carnitine, 10 mM 
l-serine, 1 μM dl-α-tocopherol acetate, and enriched with a 
lipid supplement containing 25 μM palmitic acid, 15 μM li-
noleic acid, 7 μM arachidonic acid, and 24 μM bovine serum 
albumin for another 10 days. SE were harvested after an entire 
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Fig. 1: Macroscopic and microscopic comparison of healthy skin with scar tissue and SE
A) Macroscopic overview, histological haematoxylin and eosin (H/E) staining, and immuno-histochemical α-SMA staining of human 
Nskin, NTscar, and HTscar tissue. B) Macroscopic overview, histological H/E staining, and immunohistochemical α-SMA staining of SE 
composed with P-DSC, R-DSC, and ASC. Bars macroscopic pictures = 1cm and bars microscopic stainings = 100 μm.
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Relative proliferation of keratinocytes was determined by 
quantifying the amount of housekeeping enzyme lactate de-
hydrogenase (LDH) released into the supernatant after 100% 
cell lysis with 0.1% triton x-100 as earlier described by 
Kroeze et al. (2011).
Enzyme-linked immunosorbent assay for cytokine production
All reagents were used in accordance to the manufacturer’s 
specifications. For collagen I quantification, commercially 
available elISA antibodies and recombinant proteins obtained 
from Rockland (Gilbertsville, PA, USA) were used. For IL-6, 
commercially available paired elISA antibodies and recom-
binant proteins obtained from R&D System Inc. (Minneapolis, 
MN, USA) were used. For CXCL8 quantification, a Pelipair 
reagent set (ClB, Amsterdam, the Netherlands) was used.
Statistical analysis
At least three independent experiments were performed with 
each experiment being from a different donor and having an 
intra-experimental duplicate. Importantly, all experiments us-
ing KC, P-DSC, R-DSC, and ASC were donor-matched and 
performed in parallel. Difference in thickness and contraction 
of the matrix, outgrowth of the epidermis, number of epi-
dermal cell layers, and collagen 1 secretion were compared 
between the different constructs using a repeated measures 
ANOVA test followed by Bonferroni’s multiple comparison 
test. Difference in number of epidermal cell layers in native 
skin and scar tissues were compared using a one-way analysis 
of variance test, followed by Bonferroni’s multiple compari-
son test. Differences in biomarker levels in the ASC model 
treated with therapeutic (compared to vehicle control) were 
assessed by paired t-test. Differences were considered signifi-
cant when P<0.05. 
3  Results
3.1  Qualitative macroscopic and  
microscopic comparison of native scars  
with the in vitro HTscar model
In order to determine which characteristics are typical for a 
HTscar we first compared HTscar with native human NTscar 
and Nskin. Macroscopically, HTscar is more raised and red 
than NTscar and Nskin (Fig. 1A). Microscopically, HTscar has 
a thicker epidermis than NTscar and Nskin. Rete ridges are 
almost absent in Htscar and occur to a lesser extent in Ntscar 
compared to Nskin (Ehrlich et al., 1994) (Fig. 1A). In order to 
identify the presence of myofibroblasts, which are thought to 
be mainly responsible for skin contraction after wounding, an 
α-SMA staining was performed. In HTscars α-SMA positive 
staining was not only observed around blood vessels but also 
in single cells in lower regions of the dermis. In contrast, both 
in NTscar and Nskin α-SMA staining was mainly restricted to 
blood vessels (Fig. 1A). 
Next we determined whether the Se constructed with either 
ASC, R-DSC or P-DSC showed typical macroscopic and mi-
croscopic characteristics of HTscar, NTscar and Nskin, respec-
Fig. 2: Identification of dermal parameters for HTscar 
formation
A) Thickness of dermis of SE (μm); B) relative matrix contraction  
of SE (surface area after 5 weeks of culture divided by surface  
at day 0); C) collagen 1 secretion into culture supernatants  
(ng/ml per equivalent per 24 h). Experiments were performed with 
SE constructed from three different donors each in duplicate. 
Keratinocytes, P-DSC, R-DSC, and ASC were all from the same 
donor within a single experiment. Data are presented as the 
mean (n=3 ±SEM) thickness of dermis, contraction, or secretion 
of collagen 1. Statistically significant differences were calculated 
using a repeated measures ANOVA test followed by Bonferroni’s 
multiple comparison test. *, P<0.05; **, P<0.01. 
Van den Broek et al.
Altex 29, 4/12394
tively. Macroscopically, the SeASC are more contractile than 
SeR-DSC and SeP-DSC (Fig. 1B). Similar to Htscar, microscop-
ic examination of tissue sections showed that SEASC had in-
creased thickness of the epidermis. This was not observed with 
SeR-DSC and SeP-DSC. There was increased α-SMA staining in 
Se, particularly in SeASC, where it is mainly located directly 
underneath the epidermis. The α-SMA staining was much less 
extensive, and spread throughout the dermis in SeR-DSC and 
SeP-DSC (Fig. 1B).
Clearly, Se constructed with ASC-populated matrixes rep-
resent Htscars both macroscopically and microscopically, and 
have the potential for use in an in vitro Htscar model. In con-
trast, R-DSC and P-DSC visually represent NTscar and Nskin, 
respectively. 
Before the HTscar model can be implemented, quantifiable 
and relevant parameters typical for HTscar need to be identi-
fied. Therefore, we next determined whether thickness of der-
mis, contraction, collagen 1 secretion, number of epidermal 
cell layers, and outgrowth of epidermis were suitable param-
eters. In addition, we determined whether the secretion of two 
cytokines related to wound healing, IL-6 and CXCL8, differed 
in the 3 different models.
3.2  Identification of dermal parameters  
in the HTscar model
In skin wound healing, the development of HTscar is charac-
terized by an overproduction of extracellular matrix, increased 
contraction, and augmented α-SMA expression compared to 
NTscar (Ehrlich et al., 1994). For this reason we first compared 
SeASC with SeR-DSC and SeP-DSC with regards to thickness of 
the dermis, contraction, and collagen 1 secretion (Fig. 2). 
The dermal thickness was not significantly different be-
tween the three Se (Fig. 2A). An increase in contraction is 
represented by a decrease in surface area of the SE and was 
Fig. 3: Identification of epidermal parameters for  
HTscar formation
The epidermal thickness shown as the mean number of  
keratinocyte cell layers within the epidermis of A) native tissue 
 biopsies and B) skin equivalents. C) The area of outgrowth of  
the epidermis outside of the original 1 cm diameter seeding  
area of SE (mm2). D) Keratinocyte migration towards DE condi-
tioned supernatant was assessed with a chemotactic transwell 
migration experiment. E) Relative proliferation of keratinocytes 
exposed to DE conditioned supernatant was determined by  
LDH assay. Experiments (triplicate) were performed from three  
different donors each in duplicate. Keratinocytes, P-DSC,  
R-DSC, and ASC were all from the same donor within a single 
experiment. Data are presented as the mean ± SEM (n=3).  
Statistically significant differences were calculated using a re-
peated measures ANOVA test followed by Bonferroni’s  
multiple comparison test, except for the difference in number  
of epidermal cell layers in native skin and scar tissues, which  
were compared using one-way analysis of variance test,  
followed by Bonferroni’s multiple comparison test.  
*, P<0.05; **, P<0.01.
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derived from the three types of DE. The keratinocyte migra-
tion was reduced with supernatant derived from DEASC com-
pared with supernatants derived from DER-DSC and DeP-DSC 
(Fig. 3D). The parallel proliferation experiment showed this 
decrease in migration was not due to changes in keratinoc-
yte proliferation, indicating that ASC do indeed stimulate less 
epidermal migration than R-DSC and P-DSC.
From these results, the increase in number of epidermal cell 
layers and delayed outgrowth of epidermis were identified as 
suitable epidermal parameters for assessing HTscar formation 
in vitro using Se.
3.4  Cytokine IL-6 and CXCL8 secretion 
Most probably, already at the onset of wound healing, scar 
formation is initiated. Cytokines such as IL-6 and CXCL8 are 
reported to play a role in inflammation and granulation tissue 
formation during the wound healing process (Broughton et 
al., 2006). Therefore, the secretion of IL-6 and CXCL8 was 
assessed in culture supernatants derived from SE for their use 
as potential future novel scar parameters (Fig. 4).
The secretion of IL-6 was slightly lower (trend) when ASC 
were incorporated into Se than when P-DSC were used. the 
secretion of CXCL8 by the SE was significantly lower when 
ASC were incorporated into Se than when P-DSC were used. 
From these results, decreased IL-6 and CXCL8 secretion 
were identified as a characteristic of SEASC.
 
3.5  Validation and testing of the in vitro HTscar 
model with anti-scarring agents
Clearly SE constructed from ASC populated matrixes not 
only visually represent HTscars, but also enabled quantifiable 
parameters to be identified, which are representative for HT-
observed for SEASC compared to SeR-DSC and SeP-DSC (Fig. 
2B). SeASC secreted significantly more collagen 1 compared 
to SeP-DSC (Fig. 2C). 
From these results, contraction and collagen 1 secretion 
were identified as suitable dermal parameters for assessing 
HTscar formation in vitro using Se.
3.3  Identification of epidermal parameters  
in the HTscar model
It was observed that native HTscar had a thicker epidermis 
than NTscar and Nskin (Fig. 1A). This observation was con-
firmed by quantification of the number of epidermal cell lay-
ers: HTscar showed more epidermal cell layers (7.9 ±1.6) 
than NTscars (6.9 ±1.0) and Nskin (5.8 ±0.6) (Fig. 3A). Next, 
we determined whether this increased epidermal thickness in 
native epidermis also occurred in the Htscar model. Indeed, 
SeASC had an increased number of epidermal cell layers (8.00 
±1.3) compared to SER-DSC (6.5 ±0.6) and SEP-DSC (5.3 ±1.1) 
(Fig. 3B). Notably, all of these findings correlated very close-
ly to native tissue and, in particular, Htscars had the same 
number of epidermal cell layers as SEASC. 
Since the probability of HTscar formation is increased in 
wounds with delayed wound closure (Deitch et al., 1983), we 
next determined whether ASC were responsible for the de-
layed epidermal outgrowth compared to DSC. Indeed, SeASC 
had significant slower outgrowing epidermis compared with 
SeR-DSC and SeP-DSC (Fig. 3C). However, since the contrac-
tion is also greater in SeASC compared with SeR-DSC and 
SeP-DSC, it could not be entirely excluded from these findings 
that contraction confounded this result. To exclude the con-
founder, a chemotactic transwell migration experiment was 
performed with keratinocytes using conditioned supernatant 
Fig. 4: Cytokine secretion
IL-6 and CXCL8 secretion by SE (ng/ml per equivalent per 24 h). Data are presented as the mean ± SEM secretion of IL-6 or CXCL8. 
Experiments (triplicate) were performed from three different donors, each in duplicate. Keratinocytes, P-DSC, R-DSC, and ASC were all 
from the same donor within a single experiment. Statistically significant differences between different SE were calculated using repeated 
measures ANOVA test followed by Bonferroni’s multiple comparison test. *, P<0.05.
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scars. These were increases in 1) thickness of dermis; 2) 
contraction; 3) collagen 1 secretion; 4) number of epider-
mal cell layers and decreases in 5) degree of epitheliali-
zation. In addition, SEASC showed reduced IL-6 secretion 
and reduced CxCl8 secretion. 
the Htscar model was next validated by culturing with 
positive controls, i.e., two standard therapeutics (5-fluor-
ouracil (5FU) and triamcinolon (tC)) which result in par-
tial scar correction in patients, and a negative control, i.e., 
a therapeutic that is known to be ineffective in scar reduc-
tion (1,25-dihydroxy vitamin D3 (VitD3) (tab. 1). Addi-
tionally, potential novel scar therapeutics (atorvastatin and 
all-trans-retinoic acid (RA)) were tested (tab. 1). For all 
therapeutics, vehicle controls were tested in parallel. No 
significance was found between control condition (nothing 
added) and vehicle control conditions for the selected pa-
rameters. The results of this validation study are described 
below and summarized in Tab. 2, Fig. 5, and Fig. 6. 
5-fluorouracil (5FU): standard care (partially effective 
therapeutic)
Supplementing SeASC with 5FU led to reduced contrac-
tion (Fig. 5A, 6A) and reduced number of epidermal 
cell layers of SE compared to control (6.3 ±0.8 versus 
7.8 ±0.9) (Fig. 5B, 6B). Notably, SEASC treated with 5FU 
had approximately the same number of epidermal cell lay-
ers as NTscars (6.9 ±1.0) and SER-DSC (6.5 ±0.6) (Fig. 3A, 
B). No differences were found with regards to the other 
parameters (Fig. 6). 
Triamcinolon (TC): standard care (partially effective 
therapeutic)
Supplementing TC reduced collagen 1 secretion of 
SeASC (Fig. 6A). Also, the number of epidermal cell lay-
ers of SEASC decreased after treating with TC compared to 
control (7.0 ±1.2 versus 7.8 ±0.9) (Fig. 5B, 6B). No differ-
ences were found with regards to the other parameters. 
1,25-dihydroxy vitamin D3 (VitD3): clinically non-
effective therapeutic
Supplementing VitD3 led to less contraction of SEASC 
(Fig. 5A, 6A). The number of epidermal cell layers of SEA-
SC increased after treating with VitD3 compared to control 
(9.1 ±1.1 versus 7.8 ±0.9) (Fig. 5B, 6B). Notably, SEASC 
treated with VitD3 (9.1 ±1.1) had even more epidermal cell 
layers than HTscars (7.9 ±1.6) (Fig. 3A).The secretion of 
IL-6 by SEASC was even further reduced by adding VitD3 
(Fig. 6C). No differences were found with regards to the 
other parameters.
All-trans-retinoic acid (RA): potential novel scar  
therapeutic
Supplementing potential novel scar therapeutic RA only 
partially normalized collagen 1 secretion of the HTscar 
model (SeASC). No differences were found after supple-
menting SeASC with RA with regards to the other param-
Fig. 5: Macroscopic and microscopic assessment of  
HTscar model cultured with therapeutics
A) Macroscopic overview (bars = 1 cm) and B) Histological H/E staining 
(bars = 100 µm) of SE cultured without (control condition) and with 
therapeutics (5FU, TC, RA, VitD3, atorvastatin). For all therapeutics, 
vehicle controls were tested in parallel. The vehicle control conditions 
were similar to the control condition (no vehicle added), data not shown.
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Tab. 1: Potential of different therapeutics to treat HTscars
 5FU TC VitD3 RA Atorvastatin
Clinical studies 
Standard treatment Cancer / scar (Wang Scar (Wang et al., Psoriasis (Ashcroft Leukemia (Wang Lowering 
 et al., 2009) 2009) et al., 2000) et al., 2009) cholesterol (Aarons 
     et al., 2007)
Used in clinic for Yes (Wang et al.,  Yes (Wang et al., No No No 
scar treatment 2009) 2009)
Response rate  50 to 86% (Roques 50 to 100% (Niessen No positive effect  – – 
 and Teot, 2008) et al., 1999) ( 30 patients) (van  
   der Veer et al., 2009b)  
Recurrence rate 5-10 % (Roques 9 to 50% (Niessen – – –  
 and Teot, 2008) et al., 1999)  
Preclinical studies
Neovascularization –    (Wang et al., 2009) –    (Flynn and – 
    Coleman, 2000) 
Animal experiments – – – – Yes, prevention  
     cardiac hypertrophy/  
     and adhesions  
     (Aarons et al., 2007;  
     Senthil et al., 2005)
Inflammation – Anti-inflammatory Anti-inflammatory Regulator (Wang Anti-inflammatory 
  (Wang et al., 2009) (van der Veer et al., et al., 2009) (Aarons et al., 2007) 
   2009b)  
In vitro studies
Fibroblast    (Wang et al., 2009) 
➔
(Roques and   (Greiling and   (Wang et al.,     
proliferation   Teot, 2008)  Thieroff-Ekerdt, 1996) 2009)
Collagen production     (Wang et al., 2009) ➔ (Roques and    (Greiling and    (Wang et al.,     (Aarons et al.,  
  Teot, 2008) Thieroff-Ekerdt, 1996) 2009) 2007)
Collagenase  – – –    (Wang et al.,  – 
production    2009)
Wound contraction /    (Wang et al., 2009)    (Roques and    (Greiling and    (Wang et al.,     (Jiang et al., 2010) 
myofibroblast   Teot, 2008) Thieroff-Ekerdt, 1996) 2009) 
  
Keratinocyte    (Schwartz et al.,     (Roques and    (Gibbs et al., 1996)    (Gibbs et al., 1996) – 
proliferation 1995) Teot, 2008) 
Keratinocyte – –    (Gibbs et al., 1996) – – 
differentiation  
Future prospective  Yes Yes No Potential Potential 
scar treatment
➔
➔
➔ ➔ ➔
➔
➔
➔ ➔ ➔
➔
➔ ➔ ➔ ➔ ➔
➔ ➔ ➔
➔
➔
Tab. 2: HTscar parameters and cytokine secretion 
 Therapeutics applied to in vitro HTscar model
 Standard care Not effective Potential novel
Scar parameters HT scar1 Model SEASC 2 5FU TC VitD3 RA Atorvastatin
Thickness of dermis    = = = = =     *
Contraction          * =     * = =
Collagen 1 secretion      =     * =    * =
Epidermal Thickness         *     *     * =     *
Outgrowth of epidermis     = = = = =
Cytokine secretion
IL-6 secretion ?   = =     * = =
CXCL8 secretion ?   = = = =     *
1HTscar compared to NTscar; 2ASC model compared to model containing R-DSC and P-DSC; = comparable,    increased,    decreased 
compared to control condition, ? unknown. Statistically significant difference between in vitro HTscar model cultured with therapeutics 
compared to in vitro HTscar model cultured with corresponding vehicle controls (*p < 0.05 and **p < 0.01, paired t-test)
➔
➔
➔➔
➔
➔ ➔
➔ ➔
➔ ➔
➔
➔ ➔
➔
➔
➔
➔
➔
➔
➔
➔
➔
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versus 7.8 ±0.9) (Fig. 5B, 6B). Notably, SEASC treated with 
atorvastatin had approximately the same number of epidermal 
cell layers as NTscars (6.9 ±1.0) and SER-DSC (6.5 ±0.6) (Fig. 
3A,B). The secretion of CXCL8 by SEASC was increased by 
adding atorvastatin (Fig. 6C). No differences were found with 
regards to the other parameters. Atorvastatin was the only 
therapeutic tested which resulted in partial normalization of 
three parameters. 
eters. These results indicate that RA was not an effective anti-
scar therapeutic in the Htscar model. 
Atorvastatin: potential novel scar therapeutic
Supplementing SeASC with atorvastatin reduced the thickness 
of the dermis (Fig. 5B, 6A). 
The number of epidermal cell layers of SEASC decreased 
after treating with atorvastatin compared to control (6.4 ±1.0 
Fig. 6: Validation and testing of HTscar model with therapeutics
A) Dermal parameters: thickness of dermis (μm), relative matrix contraction (surface after 5 weeks of culture divided by surface at day 0), 
and collagen 1 secretion (ng/ml per equivalent per 24 h). B) Epidermal parameters: epidermal thickness (mean number of keratinocyte 
cell layers within the epidermis) and the area of outgrowth of epidermis outside of the original 1 cm diameter seeding area (mm2).  
C) Cytokine secretion: IL-6 and CXCL8 secretion (ng/ml per equivalent per 24 h) by SE into culture supernatant was measured by ELISA. 
Vehicle = white bar; standard therapeutics = black bar; non effective therapeutics = grey bar; potential therapeutics = hatched bar. 
Experiments (triplicate) were performed with SE from three different donors, each in duplicate. Keratinocytes and ASC were all from the 
same donor within a single experiment. Data are presented as the mean ±SEM (n=3). Statistically significance between the HTscar SE 
exposed to therapeutic and its corresponding vehicle was calculated using a paired t-test. For all therapeutics, vehicle controls were 
tested in parallel. No significance was found between control condition and vehicle control conditions for the selected parameters (data 
not shown). Therefore, all control conditions are grouped together in the white bar. The experiments were performed with three donors 
each in duplicate. *, P<0.05.
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be of significance for the pathophysiology of scar formation 
and our model now provides an excellent means to investigate 
this further in parallel with in vivo patient derived-data. Of 
note, previously we have shown that ASC and dermal fibrob-
lasts both display a mesenchymal stem cell phenotype (CD31-, 
CD34+, CD45-, CD54+, CD90+, CD105+, and CD166+) and 
show similar multi-lineage differentiation potential (Kroeze 
et al., 2009). These characteristics were more pronounced for 
ASC. this suggests that, possibly, potent mesenchymal stem 
cell capacity may correlate to poor scar quality and requires 
further investigation. Although our results are in line with the 
clinical observation that HTscars show increased α-SMA com-
pared to NTscar and Nskin, it was noticed that α-SMA was 
strongly expressed directly below the basement membrane in 
the SeASC HTscar model. This indicates that cultured kerati-
nocytes may secrete a factor which stimulates differentiation 
into α-SMA positive cells. Interestingly, DEASC showed very 
little α-SMA expression, supporting this hypothesis (data not 
shown). Since the immunohistochemical staining of α-SMA 
positive cells is difficult to quantify, this biomarker was not 
selected as a scar forming parameter.
The second aim of this study was to validate the HTscar 
model with two therapeutics regularly used in the clinic for 
scar treatment (5FU and tC) (Wang et al., 2009) and one ther-
apeutic known to be unsuccessful in scar reduction (VitD3) 
(van der Veer et al., 2009b). Supplementing the Htscar model 
with 5FU resulted in partial normalization of the contraction 
and the epidermal thickness. Interestingly, the other therapeu-
tic, TC, resulted in partial normalization of a different pair 
of parameters: collagen 1 secretion and epidermal thickness. 
This finding indicates that combined therapy with 5FU and TC 
may have a better therapeutic effect than either single therapy. 
Indeed it has been shown in a clinical study (60 patients) that 
the combination of 5FU and TC does give a better response 
rate than either therapeutic alone (Asilian et al., 2006). Not all 
parameters (thickness of dermis, outgrowth of epidermis, IL-
6 secretion, and CXCL8 secretion) were favorably influenced 
by these two therapeutics. this result is in line with clinical 
results for 5FU and TC, since it is known that neither of these 
therapies can completely restore scar tissue to a normal skin 
phenotype in all patients (tab. 1) (Niessen et al., 1999; Roques 
and teot, 2008; Wang et al., 2009). Both standard therapeutics 
normalized only two parameters out of seven, indicating that 
for a therapeutic to be potentially effective, it should also par-
tially normalize at least two parameters. 
VitD3 was used as a negative control therapeutic in our 
study based on clinical evidence (van der Veer et al., 2009b). 
In line with the negative clinical results, we found an in-
creased number of epidermal cell layers after adding VitD3. 
After adding VitD3, both IL-6 and CXCL8 were even further 
reduced. However, we also observed a decrease in contraction 
in Se which may be due to VitD3 inhibiting ASC prolifera-
tion, resulting in fewer cells in the matrix at time of harvest-
ing. Indeed, FACScan flow cytometry analysis of 3mm punch 
biopsies isolated from SE showed 48% less CD90+ cells 
within the dermis of VitD3 exposed Se compared to control 
4  Discussion 
In this study we show that ASC and keratinocytes (both iso-
lated from healthy, full-thickness human skin which is read-
ily obtained as waste material after standard surgical proce-
dures) may be used to establish an in vitro Htscar model to 
test anti-scarring therapeutics. the Htscar model had similar 
characteristics as HTscars and enabled relevant and quantifi-
able HTscar parameters to be identified and tested. Our first 
results, shown in this study, indicate that the in vitro Htscar 
model may be used to test potential anti-scar therapeutics. 
Testing with combinations of known therapeutics and novel 
therapeutics is now required to further investigate the value of 
the Htscar model with regards to replacement, reduction, and 
refinement of the use of animal models.
The first part of this study involved developing the HTscar 
model and selecting relevant and quantifiable HTscar param-
eters. We found that SE constructed with ASC visually repre-
sents HTscars. In contrast, incorporation of R-DSC and P-DSC, 
which are cells isolated from the more superficial layers of the 
skin, led to SE visually representing NTscar and Nskin, respec-
tively. this observation is in line with the clinical observation 
that HTscars occur more often after the closure of full-thick-
ness wounds (Deitch et al., 1983). Relevant and quantifiable 
parameters typical for HTscars that were identified in the HT-
scar model were contraction, collagen 1 secretion, outgrowth 
of epidermis, and epidermal thickness. Additionally, two cy-
tokines typically involved in wound healing were assessed. 
The decrease in both IL-6 and CXCL8 secretion was char-
acteristic for the HTscar model only and, therefore, it would 
now be interesting to determine whether Htscars in vivo also 
showed decreased expression of these cytokines. In literature, 
no consensus was reached whether IL-6 and CXCL8 are up- or 
down-regulated during HTscar formation (Zhou et al., 1997; 
Ricketts et al., 1996; Wang et al., 2011). The confusion may 
be due to size, location, and age of the studied scar samples. 
Although we did observe an increase in collagen 1 secretion, 
no increase in thickness of the dermis was observed in the pre-
sented Htscar model compared to Se composed with R-DSC 
and P-DSC. However, the thickness of the dermis was greater 
in De when only ASC were incorporated into the matrix (with-
out keratinocytes on top) than when R-DSC or P-DSC were 
used (data not shown). At present, the reason for this is un-
known; this discrepancy between SE and DE, however, may be 
related to cultured keratinocytes being very active in secreting 
proteins which degrade the collagen matrix as it forms (Pilcher 
et al., 1998; Kahari and Saarialho-Kere, 1997).
Our results showed that dermal fibroblasts exhibited fewer 
hypertrophic scar characteristics than ASC, even though they 
have been reported to produce TGFβ1 and many cytokines 
involved in wound healing and scar formation (Nolte et al., 
2008). this indicates, in line with results reported by others, 
that dermal fibroblasts are involved in normal wound healing, 
whereas ASC may be involved in adverse scar formation (van 
den Bogaerdt et al., 2009; van der Veen et al., 2011). Our find-
ing that the SeASC model secreted less IL-6 and CXCL8 may 
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are added topically to the stratum corneum of the SE. If this 
is the case, the model will also be suitable for testing water-
insoluble therapeutics in the form of creams and ointments. 
Also, the model will need further adapting if it is to test pres-
sure and silicone dressings, both widely used in Htscar treat-
ment (Tziotzios et al., 2012). The negative control therapeutic 
VitD3 gave one false positive result (contraction) and one cor-
rectly assessed result (increase in epidermal thickness) in ad-
dition to a decreased IL-6 and IL-8 secretion. However, it may 
be possible that the false positive result is a valid result and 
that the single clinical study described was performed under 
sub-optimal conditions with regards to VitD3 concentration. In 
general, though, a single false positive result can be minimized 
due to the assessment of multiple scar parameters. 
In most academic research and during drug discovery stud-
ies, many animal experiments are used in the early phases to 
define and refine research questions and potential future ap-
plications. It is possible that these early stages of drug devel-
opment can be replaced by our human in vitro Htscar model 
system, limiting animal experiments to the final in vivo con-
firmation and risk assessment phases. Generally, these final 
phases require maximally one-tenth of the total number of 
animals used (http://www.buzzle.com/articles/animal-testing-
statistics.html).
In summary, we developed and validated an Htscar model 
using ASC and keratinocytes isolated from healthy skin and 
identified relevant and quantifiable parameters typical for HT-
scars. In line with the clinical experience, 5FU and tC only 
partially restored HTscar to normal skin phenotype. Each 
therapeutic selectively affected a different combination of 
parameters. These findings indicate that the in vitro model 
may be useful for selecting combinations of therapeutics with 
complementary properties. This will be a future area for in-
vestigation. Although the number of therapeutics tested in this 
initial study is small, our results indicate that this animal-free 
Htscar model may be used to test novel anti-scar therapeutics 
and may lead to the reduction of the use of animals in HTscar 
research.
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